MIRA Pharmaceuticals Completes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with New Obesity and Nicotine Addiction Drug Candidate
MIRA Pharmaceuticals, Inc. announced it has completed the acquisition of SKNY Pharmaceuticals, Inc., expanding its drug development pipeline to include SKNY-1, a next-generation oral therapy candidate for obesity and nicotine addiction. As part of the transaction, SKNY contributed $5 million in marketable securities to MIRA, strengthening the company's financial position. According to MIRA, SKNY-1 is designed to modulate CB1, CB2, and MAO-B pathways to address energy storage, lipid metabolism, appetite, cravings, and reward, while avoiding the psychiatric side effects seen with earlier CB1-targeting drugs. Preclinical findings highlight up to a 30% reduction in body weight without muscle loss, improved metabolic parameters, and reversal of nicotine and high-calorie food cravings. The acquisition also complements MIRA's ongoing programs, including Ketamir-2 for neuropathic pain and MIRA-55 for inflammatory pain. MIRA Pharmaceuticals stated the expansion positions the company to address major unmet medical needs across several large healthcare markets.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1079783) on September 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.